Shares of diagnostics company Vermillion Inc. (NASDAQ: VRML) have jumped more than 20% this morning following the company’s announcement of a patent approval for another of its biomarkers used to diagnose ovarian cancer. Today’s approval covers the use of “Protein C Inhibitor (PCI) in ovarian cancer tests using blood and several other sample types.”
The company’s CEO said:
The latest patent allowance further strengthens the ovarian cancer franchise behind our lead product, OVA1®, and offers creative new options to detect and manage this silent killer.
Vermillion’s shares are up 22% at $2.08 in a 52-week range of $0.97-$7.60. Volume is very heavy, already at 5x the daily average of about 522,000 shares traded.
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
